After President Trump fired widely respected Preet Bharara as the US Attorney for the Southern District of New York, he then personally interviewed candidates and selected Geoffrey Berman. US Attorney for Southern District of New York, Past and Current Preet Bharara Geoffrey Berman Geoffrey Berman then made two major decisions, the first was to recuse … Continue reading Robert Khuzami Should Recuse Himself From Leading Michael Cohen/Deutsche Bank Criminal Investigation
Disclosure: This post is both broad and detailed so that interested analysts and journalists can gather key facts and form their own opinion. Reviewing incredible schemes such as this orchestrated by Robert Mercer and Jim Simons often attract teams of analysts and reporters. This post is original fact checked independent research available free on … Continue reading How Trump Patron Robert Mercer Brilliantly Shifts Assets From The Main Street Economy, Beer Sales, Into What Bloomberg Calls “The Blackest Box in Finance.” Is Mercer indeed, like Trump, under severe financial stress?
See prior September 18. 2017 blog post for important background regarding PERS adoption of age weighted IAP accounts. Once again, it appears that younger workers are being short changed by PERS in the adoption of age weighted IAP accounts. Remarkably, there was no opportunity for public discussion on vendor selection or strategy regarding how the … Continue reading PERS IAP Accounts – Too Much Politics? Disclosure Lessons from Oregon Secretary of State Dennis Richardson
Index based investment using a company's total stock market value is a great concept and indexes such as the S&P 500 generally provide solid low cost diversification. Unfortunately, Wall Street has now applied this concept to "sectors" of the stock market without adjusting for the size of individual companies. This is not only exposing investors … Continue reading MSCI Health Care Index: A Good Measure or a Pyramid Scheme Enabler? Case Study: Johnson and Johnson and Pfizer
Doris is 85 and suffers from moisture build up in her eye, what some call wet eye. She is on Medicare and gets treated with Eylea, a Regeneron product, every 4-5 weeks. Each treatment costing $6,200. That is more than $70,000 per year even though Doris never made more than $40,000 while working. … Continue reading Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs
Senator McConnell's Dilemma: To Serve Patients or Investors? When evaluating health care investments it is important to analyze the structure of leading drug and medical equipment companies. A close look indeed reveals a derivative driven system in which private equity and hedge funds increase demand for drug payments by purchasing the rights … Continue reading Is Patient Health Being Mortgaged via Derivatives as Homes Were During the Financial Crisis?